Ildong Pharmaceutical : Interim Report on Business Performance (Fair Disclosure)
February 17, 2022 at 03:54 am EST
Share
Interim Report on Business Performance (Fair Disclosure)
※ The following are interim figures, and may be different from final data.
1. Details of business performance
in KRW mn, %
Category
Current period
Previous period
Changes over previous period (%)
Same period of last year
Changes over same period of last year (%)
(4Q.21)
(3Q.21)
(4Q.20)
Sales
Current
142,387
142,256
0.1%
138,552
2.8%
Cumulative
559,145
416,758
-
560,964
-0.3%
Operating income
Current
-17,823
-13,951
-27.8%
-5,864
-203.9%
Cumulative
-54,327
-36,504
-
5,598
Turned into a deficit
Net income from continuing operation before income tax
Current
-126,114
-7,811
-1514.6%
-14,650
-760.8%
Cumulative
-139,339
-13,225
-
-10,022
-1290.3%
Net income
Current
-93,172
-4,461
-1988.6%
-19,073
-388.5%
Cumulative
-98,892
-5,720
-
-13,105
-654.6%
-
-
-
-
-
-
2. Details of information released
Information provider
CP Team
Information recipients
Institutional and individual investors, analysts and the media
Date & time of information released
Feb. 17, 2022, 17:17(+Seoul time)
Title and place of event held
-
3. Contact points (department/phone number)
CP Team(02-526-3357)
4. Other matters to be factored into investment decisions
- The above results are separate financial statements based on K-IFRS.
- Above results prior to an external review are subject to change after a review by external auditors.
- Accumulated amount of the net profit from continuing operation before income tax in current term(4Q. 21) includes 75,439 million(KRW) of loss on valuation of derivative instruments financial liabilities related to convertible bonds.
※ Related disclosure
-
Attachments
Original Link
Original Document
Permalink
Disclaimer
Il Dong Pharmaceutical Co. Ltd. published this content on 17 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 February 2022 08:53:04 UTC.